Oncogenic codon 13 NRAS mutation in a primary mesenchymal brain neoplasm and nevus of a child with neurocutaneous melanosis

Acta Neuropathologica Communications

Volumn 2, Issue 1, 2014, Pages

  Shih, Francis ^a   Yip, Stephen ^b   McDonald, Patrick J ^c   Chudley, Albert E ^c   Del Bigio, Marc R ^a  

^a Diagnostic Services of Manitoba Inc   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Brain tumor; Genetic mutation; Melanosis; Somatic mosaicism

Indexed keywords

CD34 ANTIGEN; CODON; GLIAL FIBRILLARY ACIDIC PROTEIN; GUANOSINE TRIPHOSPHATASE; MEMBRANE PROTEIN; MUCIN 1; NRAS PROTEIN, HUMAN; PROTEIN P53; VIMENTIN;

BRAIN TUMOR; CASE REPORT; CHOROID PLEXUS TUMOR; CODON; COMPLICATION; FEMALE; GENETICS; HUMAN; MELANOSIS; METABOLISM; MUTATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PHAKOMATOSIS; PRESCHOOL CHILD; SKIN TUMOR;

ANTIGENS, CD34; BRAIN NEOPLASMS; CHILD, PRESCHOOL; CHOROID PLEXUS NEOPLASMS; CODON; FEMALE; GLIAL FIBRILLARY ACIDIC PROTEIN; GTP PHOSPHOHYDROLASES; HUMANS; MAGNETIC RESONANCE IMAGING; MELANOSIS; MEMBRANE PROTEINS; MUCIN-1; MUTATION; NEUROCUTANEOUS SYNDROMES; SKIN NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53; VIMENTIN;

EID: 84965083580     PISSN: None     EISSN: 20515960     Source Type: Journal    
DOI: 10.1186/s40478-014-0140-8     Document Type: Article

References (50)

1. Pavlidou E, Hagel C, Papavasilliou A, Giouroukos S, Panteliadis C: Neurocutaneous melanosis: report of three cases and up-to-date review. J Child Neurol 2008, 23: 1382-1391.
2. Makkar HS, Frieden IJ: Neurocutaneous melanosis. Semin Cutan Med Surg 2004, 23: 138-144.
3. Kinsler VA, Anderson G, Latimer B, Natarajan D, Healy E, Moore GE, Sebire NJ: Immunohistochemical and ultrastructural features of congenital melanocytic naevus cells support a stem-cell phenotype. Br J Dermatol 2013, 169: 374-383.
4. Melanosis, Neurocutaneous; NCMS; MIM#249400. Johns Hopkins University, Baltimore, MD; 2014.
5. Kinsler VA, Thomas AC, Ishida M, Bulstrode NW, Loughlin S, Hing S, Chalker J, McKenzie K, Abu-Amero S, Slater O, Chanudet E, Palmer R, Morrogh D, Stanier P, Healy E, Sebire NJ, Moore GE: Multiple congenital melanocytic nevi and neurocutaneous melanosis are caused by postzygotic mutations in codon 61 of NRAS. J Invest Dermatol 2013, 133: 2229-2236.
6. Kusters-Vandevelde HV, Willemsen AE, Groenen PJ, Kusters B, Lammens M, Wesseling P, Djafarihamedani M, Rijntjes J, Delye H, Willemsen MA, van Herpen CM, Blokx WA: Experimental treatment of NRAS-mutated neurocutaneous melanocytosis with MEK162, a MEK-inhibitor. Acta Neuropathol Commun 2014, 2: 41.
7. Etchevers HC: Hiding in plain sight: molecular genetics applied to giant congenital melanocytic nevi. J Invest Dermatol 2014, 134: 879-882.
8. Bekiesinska-Figatowska M, Szczygielski O, Boczar M, Madzik J, Klepacka T, Michalak E, Romaniuk-Doroszewska A, Uliasz M, Peczkowski P, Sawicka E: Neurocutaneous melanosis in children with giant congenital melanocytic nevi. Clin Imaging 2014, 38: 79-84.
9. Ramaswamy V, Delaney H, Haque S, Marghoob A, Khakoo Y: Spectrum of central nervous system abnormalities in neurocutaneous melanocytosis. Dev Med Child Neurol 2012, 54: 563-568.
10. Scattolin MA, Lin J, Peruchi MM, Rocha AJ, Masruha MR, Vilanova LC: Neurocutaneous melanosis: follow-up and literature review. J Neuroradiol 2011, 38: 313-318.
11. Yang MM, Singhal A, Rassekh SR, Yip S, Eydoux P, Dunham C: Possible differentiation of cerebral glioblastoma into pleomorphic xanthoastrocytoma: an unusual case in an infant. J Neurosurg Pediatr 2012, 9: 517-523.
12. Rokitansky J: Ein ausgezeichneter Fall von Pigment-mal mit ausgebreiteter Pigmentierung der inneren Hin- und Ruchenmarkshaute. Allg Wien Med Z 1861, 6: 113-116.
13. Fu YJ, Morota N, Nakagawa A, Takahashi H, Kakita A: Neurocutaneous melanosis: surgical pathological features of an apparently hamartomatous lesion in the amygdala. J Neurosurg Pediatr 2010, 6: 82-86.
14. De Cock J, Snauwaert J, Van Rompaey W, Morren MA, Demaerel P: A newborn with neurocutaneous melanocytosis and Dandy-Walker malformation. Pediatr Neurol 2014, 50: 276-278.
15. Frieden IJ, Williams ML, Barkovich AJ: Giant congenital melanocytic nevi: brain magnetic resonance findings in neurologically asymptomatic children. J Am Acad Dermatol 1994, 31: 423-429.
16. Gerami P, Paller AS: Making a mountain out of a molehill: NRAS, mosaicism, and large congenital nevi. J Invest Dermatol 2013, 133: 2127-2130.
17. Charbel C, Fontaine RH, Malouf GG, Picard A, Kadlub N, El-Murr N, How-Kit A, Su X, Coulomb-L'Hermine A, Tost J, Mourah S, Aractingi S, Guegan S: NRAS mutation is the sole recurrent somatic mutation in large congenital melanocytic nevi. J Invest Dermatol 2014, 134: 1067-1074.
18. Bauer J, Curtin JA, Pinkel D, Bastian BC: Congenital melanocytic nevi frequently harbor NRAS mutations but no BRAF mutations. J Invest Dermatol 2007, 127: 179-182.
19. Hamm H: Cutaneous mosaicism of lethal mutations. Am J Med Genet 1999, 85: 342-345.
20. Cirstea IC, Kutsche K, Dvorsky R, Gremer L, Carta C, Horn D, Roberts AE, Lepri F, Merbitz-Zahradnik T, Konig R, et al.: A restricted spectrum of NRAS mutations causes Noonan syndrome. Nat Genet 2010, 42: 27-29.
21. Ross AL, Sanchez MI, Grichnik JM: Molecular nevogenesis. Dermatol Res Pract 2011, 2011: 463184.
22. Ball NJ, Yohn JJ, Morelli JG, Norris DA, Golitz LE, Hoeffler JP: Ras mutations in human melanoma: a marker of malignant progression. J Invest Dermatol 1994, 102: 285-290.
23. van Elsas A, Zerp SF, van der Flier S, Kruse KM, Aarnoudse C, Hayward NK, Ruiter DJ, Schrier PI: Relevance of ultraviolet-induced N-ras oncogene point mutations in development of primary human cutaneous melanoma. Am J Pathol 1996, 149: 883-893.
24. Pavey S, Johansson P, Packer L, Taylor J, Stark M, Pollock PM, Walker GJ, Boyle GM, Harper U, Cozzi SJ, Hansen K, Yudt L, Schmidt C, Hersey P, Ellem KA, O'Rourke MG, Parsons PG, Meltzer P, Ringner M, Hayward NK: Microarray expression profiling in melanoma reveals a BRAF mutation signature. Oncogene 2004, 23: 4060-4067.
25. Sekine S, Nakanishi Y, Ogawa R, Kouda S, Kanai Y: Esophageal melanomas harbor frequent NRAS mutations unlike melanomas of other mucosal sites. Virchows Arch 2009, 454: 513-517.
26. Dessars B, De Raeve LE, Morandini R, Lefort A, El Housni H, Ghanem GE, Van den Eynde BJ, Ma W, Roseeuw D, Vassart G, Libert F, Heimann P: Genotypic and gene expression studies in congenital melanocytic nevi: insight into initial steps of melanotumorigenesis. J Invest Dermatol 2009, 129: 139-147.
27. Phadke PA, Rakheja D, Le LP, Selim MA, Kapur P, Davis A, Mihm MC Jr, Hoang MP: Proliferative nodules arising within congenital melanocytic nevi: a histologic, immunohistochemical, and molecular analyses of 43 cases. Am J Surg Pathol 2011, 35: 656-669.
28. Colombino M, Capone M, Lissia A, Cossu A, Rubino C, De Giorgi V, Massi D, Fonsatti E, Staibano S, Nappi O, Pagani E, Casula M, Manca A, Sini M, Franco R, Botti G, Caraco C, Mozzillo N, Ascierto PA, Palmieri G: BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma. J Clin Oncol 2012, 30: 2522-2529.
29. Zuniga S, Las Heras J, Benveniste S: Rhabdomyosarcoma arising in a congenital giant nevus associated with neurocutaneous melanosis in a neonate. J Pediatr Surg 1987, 22: 1036-1038.
30. Paulus W, Slowik F, Jellinger K: Primary intracranial sarcomas: histopathological features of 19 cases. Histopathology 1991, 18: 395-402.
31. Toro JR, Travis LB, Wu HJ, Zhu K, Fletcher CD, Devesa SS: Incidence patterns of soft tissue sarcomas, regardless of primary site, in the surveillance, epidemiology and end results program, 1978-2001: An analysis of 26,758 cases. Int J Cancer 2006, 119: 2922-2930.
32. Tun K, Ozen O, Kaptanoglu E, Gurcan O, Beskonakli E, Celasun B: Primary intracranial low-grade fibromyxoid sarcoma (Evans tumor). J Clin Neurosci 2008, 15: 1298-1301.
33. Ricarte-Filho JC, Ryder M, Chitale DA, Rivera M, Heguy A, Ladanyi M, Janakiraman M, Solit D, Knauf JA, Tuttle RM, Ghossein RA, Fagin JA: Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1. Cancer Res 2009, 69: 4885-4893.
34. Buccoliero AM, Castiglione F, Garbini F, Rossi Degl'Innocenti D, Moncini D, Franchi A, Paglierani M, Simoni A, Baroni G, Daniele D, Sardi I, Giordano F, Mussa F, Arico M, Genitori L, Taddei GL: Primary cerebral myxofibrosarcoma: clinical, morphologic, immunohistochemical, molecular, and ultrastructural study of an infrequent tumor in an extraordinary localization. J Pediatr Hematol Oncol 2011, 33: e279-e283.
35. Stratton MR, Fisher C, Gusterson BA, Cooper CS: Detection of point mutations in N-ras and K-ras genes of human embryonal rhabdomyosarcomas using oligonucleotide probes and the polymerase chain reaction. Cancer Res 1989, 49: 6324-6327.
36. Doisaki S, Muramatsu H, Shimada A, Takahashi Y, Mori-Ezaki M, Sato M, Kawaguchi H, Kinoshita A, Sotomatsu M, Hayashi Y, Furukawa-Hibi Y, Yamada K, Hoshino H, Kiyoi H, Yoshida N, Sakaguchi H, Narita A, Wang X, Ismael O, Xu Y, Nishio N, Tanaka M, Hama A, Koike K, Kojima S: Somatic mosaicism for oncogenic NRAS mutations in juvenile myelomonocytic leukemia. Blood 2012, 120: 1485-1488.
37. De Filippi P, Zecca M, Lisini D, Rosti V, Cagioni C, Carlo-Stella C, Radi O, Veggiotti P, Mastronuzzi A, Acquaviva A, D'Ambrosio A, Locatelli F, Danesino C: Germ-line mutation of the NRAS gene may be responsible for the development of juvenile myelomonocytic leukaemia. Br J Haematol 2009, 147: 706-709.
38. Harrisingh MC, Lloyd AC: Ras/Raf/ERK signalling and NF1. Cell Cycle 2004, 3: 1255-1258.
39. Boccaccio C, Comoglio PM: Invasive growth: a MET-driven genetic programme for cancer and stem cells. Nat Rev Cancer 2006, 6: 637-645.
40. Takayama H, La Rochelle WJ, Anver M, Bockman DE, Merlino G: Scatter factor/hepatocyte growth factor as a regulator of skeletal muscle and neural crest development. Proc Natl Acad Sci U S A 1996, 93: 5866-5871.
41. Takayama H, LaRochelle WJ, Sharp R, Otsuka T, Kriebel P, Anver M, Aaronson SA, Merlino G: Diverse tumorigenesis associated with aberrant development in mice overexpressing hepatocyte growth factor/scatter factor. Proc Natl Acad Sci U S A 1997, 94: 701-706.
42. Takayama H, Nagashima Y, Hara M, Takagi H, Mori M, Merlino G, Nakazato Y: Immunohistochemical detection of the c-met proto-oncogene product in the congenital melanocytic nevus of an infant with neurocutaneous melanosis. J Am Acad Dermatol 2001, 44: 538-540.
43. Tengs T, Lee JC, Paez JG, Zhao X, LaFramboise T, Giannoukos G, Thomas RK: A transforming MET mutation discovered in non-small cell lung cancer using microarray-based resequencing. Cancer Lett 2006, 239: 227-233.
44. Neklason DW, Done MW, Sargent NR, Schwartz AG, Anton-Culver H, Griffin CA, Ahnen DJ, Schildkraut JM, Tomlinson GE, Strong LC, Miller AR, Stopfer JE, Burt RW: Activating mutation in MET oncogene in familial colorectal cancer. BMC Cancer 2011, 11: 424.
45. Ma PC, Kijima T, Maulik G, Fox EA, Sattler M, Griffin JD, Johnson BE, Salgia R: c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions. Cancer Res 2003, 63: 6272-6281.
46. Voortman J, Harada T, Chang RP, Killian JK, Suuriniemi M, Smith WI, Meltzer PS, Lucchi M, Wang Y, Giaccone G: Detection and therapeutic implications of c-Met mutations in small cell lung cancer and neuroendocrine tumors. Curr Pharm Des 2013, 19: 833-840.
47. Tyner JW, Fletcher LB, Wang EQ, Yang WF, Rutenberg-Schoenberg ML, Beadling C, Mori M, Heinrich MC, Deininger MW, Druker BJ, Loriaux MM: MET receptor sequence variants R970C and T992I lack transforming capacity. Cancer Res 2010, 70: 6233-6237.
48. Flores-Sarnat L: Hemimegalencephaly: part 1. Genetic, clinical, and imaging aspects. J Child Neurol 2002, 17: 373-384.
49. Flores-Sarnat L: Neurocutaneous melanocytosis. Handb Clin Neurol 2013, 111: 369-388.
50. Lee JH, Huynh M, Silhavy JL, Kim S, Dixon-Salazar T, Heiberg A, Scott E, Bafna V, Hill KJ, Collazo A, Funari V, Russ C, Gabriel SB, Mathern GW, Gleeson JG: De novo somatic mutations in components of the PI3K-AKT3-mTOR pathway cause hemimegalencephaly. Nat Genet 2012, 44: 941-945.